Artigo Acesso aberto Revisado por pares

Availability of Hepatitis B Vaccine That Does Not Contain Thimerosal as a Preservative

1999; American Medical Association; Volume: 282; Issue: 13 Linguagem: Inglês

10.1001/jama.282.13.1219

ISSN

1538-3598

Tópico(s)

Hepatitis B Virus Studies

Resumo

On August 27, 1999, Merck Vaccine Division (Merck & Co., Inc., West Point, Pennsylvania) received approval from the Food and Drug Administration (FDA) of a supplement to Merck's license application to include the manufacture of single-antigen preservative-free hepatitis B vaccine (Recombivax HB, Pediatric); distribution is expected to begin September 13, 1999. In addition, SmithKline Beecham Biologicals (SmithKline Beecham, Philadelphia, Pennsylvania), expects to make single-antigen preservative-free hepatitis B vaccine (Engerix-B, Pediatric) available in the near future. Further product information will be provided when it becomes available. Product packaging and labels will indicate that these vaccines do not contain preservative.

Referência(s)
Altmetric
PlumX